KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 4605 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Efficacy and Safety of Imsidolimab for Generalized Pustular Psoriasis. PMID 42047557 · NEJM Evid · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Glenzocimab Efficacy and Safety Added to Intravenous Thrombolysis With or Without Mechanical Thrombectomy in Patients With Acute Ischemic Stroke-ACTISAVE: A Prospective, Randomized, Double-Blind Study. PMID 42044230 · Stroke · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Comparing the efficacy and safety of biosimilar BAT2506 with reference golimumab in patients with active psoriatic arthritis: 24-week results of a phase 3, multicenter, double-blind, randomized, parallel-group study. PMID 42021476 · Expert Opin Biol Ther · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy, immunogenicity, and safety of a cell culture-derived quadrivalent influenza vaccine compared with a non-influenza vaccine in infants and children across five influenza seasons: a phase 3, multinational, observer-blind, randomised controlled trial. PMID 41962984 · Lancet Child Adolesc Health · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Baseline Alkaline Phosphatase Impacts Response Rates in Primary Biliary Cholangitis: Exploring Response to Elafibranor in ELATIVE. PMID 41937506 · Liver Int · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pitavastatin effects on lipids in relation to major adverse cardiovascular events: a REPRIEVE secondary analysis. PMID 41936375 · Lancet HIV · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Minimal important differences of EORTC QLQ-C30 and QLQ-BR23 for metastatic breast cancer patients in a Japanese population: results from the RESQ trial. PMID 41910921 · Breast Cancer · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L B
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Polymyxin B haemoadsorption in endotoxic septic shock (Tigris): a multicentre, open-label, Bayesian, randomised, controlled, phase 3 trial. PMID 41887242 · Lancet Respir Med · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Procalcitonin testing combined with NEWS2 evaluation compared with usual care based on NEWS2 for identification of sepsis and antibiotic initiation in the emergency department in England and Wales (PRONTO): a multicentre, randomised, controlled, open-label, phase 3 trial. PMID 41881047 · Lancet Respir Med · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Timing of Pegfilgrastim Administration and Pegfilgrastim-Induced Bone Pain : A Prospective, Randomized, Phase 3 Trial. PMID 41871353 · Ann Intern Med · 2026-May The trial is a randomized Phase III study in human oncology (breast cancer) with a drug intervention (pegfilgrastim). However, the primary and secondary endpoints are not time-to-event efficacy measures (OS, PFS, DFS, etc.). The primary endpoint is the AUC of a daily pain score, and secondary endpoints are incidence rates of pain, neutropenia, and febrile neutropenia. No Kaplan-Meier, hazard ratio, or other time-to-event analysis is reported. Therefore, it does not meet the time-to-event criterion.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Mycophenolate mofetil versus prednisone for the initial treatment of idiopathic steroid-sensitive nephrotic syndrome in children in Germany (INTENT): a multicentre, open-label, randomised, controlled, parallel-group, non-inferiority, phase 3 trial. PMID 41856160 · Lancet Child Adolesc Health · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Spleen Volume Reduction and Transfusion Independence With Momelotinib Versus Ruxolitinib and Associated Overall Survival With Momelotinib in JAK Inhibitor-Naive Patients With Myelofibrosis and Anemia: Subgroup Analyses of SIMPLIFY-1. PMID 41813472 · Clin Lymphoma Myeloma Leuk · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Ixekizumab in children with active psoriatic and enthesitis-related juvenile idiopathic arthritis (COSPIRIT-JIA): a multicentre, open-label, 16-week, Bayesian trial including a randomised reference group to adalimumab. PMID 41785908 · Lancet Rheumatol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Dose-Escalation Regimens for Incretin Mimetics in Type 2 Diabetes Are Associated With Tolerance for Nausea and Vomiting. PMID 41757397 · Diabetes Obes Metab · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Effect of ivarmacitinib on swelling and tenderness in small and large joints and imaging changes in patients with moderate-to-severe RA: a post hoc analysis of a phase III clinical trial. PMID 41741728 · Naunyn Schmiedebergs Arch Pharmacol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Normal tissue complication probability models for gastrointestinal toxicity after adjuvant (chemo)radiotherapy for cervical cancer in the PARCER trial. PMID 41698508 · Radiother Oncol · 2026-May This is an original secondary analysis from a Phase III randomized trial (PARCER), but it does not report a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, etc.) with KM survival curves or HR. The study focuses on developing normal tissue complication probability (NTCP) models for gastrointestinal toxicity outcomes, which are safety/toxicity endpoints, not efficacy endpoints for a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Baseline characteristics of patients recruited to the mannitol for cerebral oedema after acute intracerebral haemorrhage (MACE-ICH) trial. PMID 41690237 · Clin Neurol Neurosurg · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of sepiapterin versus sapropterin in patients with phenylketonuria: Results from the Phase 3, randomized, crossover, open-label, active-controlled AMPLIPHY trial. PMID 41616812 · Metabolism · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Single nucleotide polymorphisms in the bepirovirsen binding site have limited impact on treatment response in chronic hepatitis B. PMID 41544767 · J Hepatol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Lactate Dehydrogenase and Outcomes in Patients With HF and Reduced Ejection Fraction: Insights From GALACTIC-HF. PMID 41528277 · JACC Heart Fail · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early and Sustained Improvements in Sense of Smell With Tezepelumab Treatment in Patients With Chronic Rhinosinusitis With Nasal Polyps (WAYPOINT). PMID 41493192 · Int Forum Allergy Rhinol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Early Response to Vunakizumab at Week 2 Predicts Favourable Long-Term Efficacy in Patients With Moderate-To-Severe Plaque Psoriasis: A Post Hoc Analysis of a Phase III, Randomised Controlled Trial. PMID 41479228 · Immunology · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Lebrikizumab is efficacious in adults and adolescents with moderate-to-severe atopic dermatitis regardless of atopic comorbidities. PMID 41435984 · Ann Allergy Asthma Immunol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of tirzepatide versus semaglutide in achieving therapeutic targets in type 2 diabetes: a post hoc analysis of the SURPASS-2 Trial. PMID 41419618 · Diabetologia · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Rapid improvement of itch with nemolizumab in atopic dermatitis and prurigo nodularis phase 3 studies. PMID 41401055 · J Eur Acad Dermatol Venereol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of brodalumab in palmoplantar pustulosis: A 68-week randomized Phase 3 trial. PMID 41239899 · J Eur Acad Dermatol Venereol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: Ninety-Six-Week Results from the Randomized Phase 2/3 PHOTON Trial. PMID 41223900 · Ophthalmology · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy of up to 4 years of tralokinumab in adults with moderate-to-severe atopic dermatitis. PMID 41217071 · J Eur Acad Dermatol Venereol · 2026-May 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Acoltremon Ophthalmic Solution 0.003% for Signs and Symptoms of Dry Eye Disease: Results of Phase 3 Pivotal COMET-2 and COMET-3 Studies. PMID 41038456 · Ophthalmology · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Fluid/function correlation using AI-based quantification versus central subfield thickness in treatment-naïve and pre-treated patients with neovascular AMD in a real-world setting. PMID 40965041 · Acta Ophthalmol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Impact of Extended Risankizumab Treatment in Patients With Ulcerative Colitis Who Did Not Respond to Induction Treatment. PMID 40953785 · Clin Gastroenterol Hepatol · 2026-May 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Oral PCSK9 Inhibitor Enlicitide Versus Oral Nonstatin Therapies: A Phase 3 Randomized Clinical Trial. PMID 42017875 · J Am Coll Cardiol · 2026-Mar-30 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Mavacamten in Adolescents with Obstructive Hypertrophic Cardiomyopathy. PMID 41910394 · N Engl J Med · 2026-Mar-29 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Switch to single-tablet bictegravir-lenacapavir from a complex HIV regimen (ARTISTRY-1): a randomised, open-label, phase 3 clinical trial. PMID 41763229 · Lancet · 2026-Mar-28 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Associations between perceived neighborhood environment and physical activity among breast cancer patients engaged in a physical activity program concomitant to cancer treatment: cross-sectional and longitudinal analyses in the DISCO trial (DiscoSpace). PMID 41882725 · Int J Behav Nutr Phys Act · 2026-Mar-26 The report is an original result of a human Phase III RCT in oncology, but it is a secondary observational analysis (nested within a trial) with a non-drug intervention (physical activity) and non-time-to-event endpoints (physical activity, walking distance). It does not meet the criteria for inclusion as a primary or key secondary efficacy analysis with a time-to-event endpoint and a drug intervention.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Randomized trial of low-dose, ultrasound-assisted thrombolysis or heparin for pulmonary embolism. PMID 41610160 · Cardiovasc Res · 2026-Mar-26 未发现恶性肿瘤人群证据。
L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term safety and efficacy of ponesimod in participants with relapsing multiple sclerosis: results from the phase 3 OPTIMUM 5-year long term extension study. PMID 41879928 · J Neurol · 2026-Mar-25 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and safety of once-weekly somatrogon in adults with growth hormone deficiency: a randomized phase 3 study. PMID 41879875 · Pituitary · 2026-Mar-25 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Fluconazole plus flucytosine versus fluconazole alone for adults with HIV-associated cryptococcal antigenaemia identified through screening: a multi-centre phase III randomised-controlled trial. PMID 41877274 · Trials · 2026-Mar-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Concizumab in hemophilia with inhibitors: longer-term efficacy and safety results from the phase 3 explorer7 study. PMID 41499759 · Blood Adv · 2026-Mar-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Efficacy and Safety of NFL-101 as a Smoking Cessation Therapy: A Randomized Phase II Clinical Trial CESTO2. PMID 40884488 · Nicotine Tob Res · 2026-Mar-24 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Perfluorohexyloctane eye drops in treating dry eye disease associated with meibomian gland dysfunction: a post hoc analysis by baseline severity. PMID 41870723 · Int Ophthalmol · 2026-Mar-23 属于事后亚组、二次、生活质量或卫生经济学分析,不作为原始随机试验结果纳入。
H L
旧查询独有 excludedpost_hoc_or_secondary_analysis pending 0 Figure · 0 Panel · risk -
Efficacy and safety of once-daily oral orforglipron compared with oral semaglutide in adults with type 2 diabetes (ACHIEVE-3): a multinational, multicentre, non-inferiority, open-label, randomised, phase 3 trial. PMID 41765029 · Lancet · 2026-Mar-21 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Pharmacodynamics of Camizestrant Treatment in Postmenopausal Women With Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Primary Breast Cancer: Results From the Randomized, Presurgical SERENA-3 Study. PMID 41628308 · J Clin Oncol · 2026-Mar-20 The study meets criteria for oncology, human, randomized, phase 3, drug intervention, and is an original result report. However, it is excluded because its primary endpoint is not a time-to-event efficacy endpoint; it reports pharmacodynamic changes (Ki67, ER) rather than OS, PFS, or similar survival outcomes with associated Kaplan-Meier or HR data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low-concentration bimatoprost 0.01% and timolol 0.1% eye gel versus bimatoprost 0.03% and timolol 0.5% eye drops in open-angle glaucoma or ocular hypertension: a phase III randomised study. PMID 41093358 · Br J Ophthalmol · 2026-Mar-20 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Long-term protection of an inactivated enterovirus type 71 vaccine against hand, foot, and mouth diseases in children: a modelling study. PMID 41650673 · Vaccine · 2026-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Ivarmacitinib ointment in treatment of adults with mild-to-moderate atopic dermatitis: phase III of a randomized double-blind placebo-controlled phase II/III clinical trial. PMID 41317338 · Br J Dermatol · 2026-Mar-19 未发现恶性肿瘤人群证据。
H L
旧查询独有 excludednon_oncology pending 0 Figure · 0 Panel · risk -
Cluster randomised controlled trial for service delivery redesign of primary care for people with diabetes: study protocol. PMID 41857847 · BMJ Open · 2026-Mar-18 方案论文未报告临床试验结果。
H L
旧查询独有 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Identification of tofersen PD-response biomarkers in VALOR clinical trial CSF via multiplexed quantitative proteomics. PMID 41850233 · Cell Rep Med · 2026-Mar-17 The study is a Phase III randomized trial of a drug (tofersen) in humans, but it is not an oncology study (ALS is a neurodegenerative disease). Furthermore, the primary analysis is a pharmacodynamic biomarker study (proteomics), not a time-to-event efficacy endpoint (OS, PFS, etc.) report.
H L
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Rapid and Sustained Response of Biochemically Uncontrolled Acromegaly to Once-daily Oral Paltusotine Treatment. PMID 41128642 · J Clin Endocrinol Metab · 2026-Mar-17 The study is a Phase III randomized trial of a drug for acromegaly, which is not a human malignant neoplasm. The primary efficacy endpoint is a biochemical response (IGF-I normalization), not a time-to-event endpoint like OS, PFS, or DFS, and there is no indication of Kaplan-Meier analysis or hazard ratios for survival/time-to-event data.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -